Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases
出版年份 2014 全文链接
标题
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases
作者
关键词
-
出版物
Therapeutic Advances in Gastroenterology
Volume 8, Issue 2, Pages 66-82
出版商
SAGE Publications
发表日期
2014-11-13
DOI
10.1177/1756283x14558193
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist
- (2015) Olivier Dewit et al. GASTROENTEROLOGY
- 90 Safety and Efficacy of Laquinimod in Inducing Clinical and Biochemical Improvement in Active Crohn's Disease: Results of an Exploratory Trial
- (2015) Geert R. D'Haens et al. GASTROENTEROLOGY
- Review article: anti-adhesion therapies for inflammatory bowel disease
- (2014) T. Lobatón et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014
- (2014) Anil Asthana et al. CURRENT DRUG TARGETS
- Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis
- (2014) Michel Varrin-Doyer et al. EXPERIMENTAL NEUROLOGY
- 863 Tralokinumab (CAT-354), an Interleukin 13 Antibody, in Moderate to Severe Ulcerative Colitis: A Phase 2A Randomized Placebo-Controlled Study
- (2014) Silvio Danese et al. GASTROENTEROLOGY
- P516 Discrepancy between fecal biomarkers and their intestinal gene expression in ulcerative colitis: Results from an anti-IL-13 antibody study
- (2014) W. Reinisch et al. Journal of Crohns & Colitis
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket
- (2014) Diane D'allard et al. PLoS One
- Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases
- (2013) M. Rinaudo-Gaujous et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Disease-Modifying Anti-Inflammatory Bowel Disease Drugs (DMAIDs): The Missing Term in the Literature
- (2013) Laurent Peyrin-Biroulet AMERICAN JOURNAL OF GASTROENTEROLOGY
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib: Janus Bifrons in Ulcerative Colitis Treatment
- (2013) Laurent Peyrin–Biroulet et al. GASTROENTEROLOGY
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- 11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial
- (2013) B. Sands et al. Journal of Crohns & Colitis
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
- (2013) Mehmet Coskun et al. PHARMACOLOGICAL RESEARCH
- Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy
- (2013) Klaudia Farkas et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
- (2012) Arthur Kavanaugh et al. ARTHRITIS AND RHEUMATISM
- Biosimilars: what clinicians should know
- (2012) M. Weise et al. BLOOD
- Role of mast cells in mucosal diseases: current concepts and strategies for treatment
- (2012) Lianne Beunk et al. Expert Review of Clinical Immunology
- Interleukin 13 and its role in gut defence and inflammation
- (2012) Peter Mannon et al. GUT
- Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease
- (2012) Giovanni Monteleone et al. MOLECULAR THERAPY
- IL-12 family cytokines: immunological playmakers
- (2012) Dario A A Vignali et al. NATURE IMMUNOLOGY
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Conventional Medical Management of Inflammatory Bowel Disease
- (2011) Daniel Burger et al. GASTROENTEROLOGY
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- New therapies for inflammatory bowel disease: from the bench to the bedside
- (2011) Silvio Danese GUT
- Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
- (2011) Laurent Peyrin-Biroulet et al. GUT
- Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study
- (2011) Asit Parikh et al. INFLAMMATORY BOWEL DISEASES
- Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies
- (2011) Kearkiat Praditpornsilpa et al. KIDNEY INTERNATIONAL
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?
- (2010) Geert R D'Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
- (2010) Richard J. Riese et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis
- (2010) W. J. Sandborn et al. GUT
- The Natural History of Adult Crohn's Disease in Population-Based Cohorts
- (2009) Laurent Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- Controlling the cost of innovative cancer therapeutics
- (2009) Nafees N. Malik Nature Reviews Clinical Oncology
- Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
- (2009) Jacques Tebib et al. ARTHRITIS RESEARCH & THERAPY
- Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
- (2008) Jonathan Kay et al. ARTHRITIS AND RHEUMATISM
- Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
- (2008) Brian G. Feagan et al. Clinical Gastroenterology and Hepatology
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study
- (2008) Brian G. Feagan et al. GASTROENTEROLOGY
- Crohn's disease: beyond antagonists of tumour necrosis factor
- (2008) Laurent Peyrin-Biroulet et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now